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Chapter I. Introduction 
 
1. General remark 
 1-1. Significant impact on our life by influenza virus infection 
Influenza virus was the first isolated from pigs by Shope and Lewis in 
1930 (Shope and Lewis 1931).  It is one of the most dangerous viruses which 
constantly circulate in many animal hosts, such as humans, birds, horses, dogs 
an pigs.  This virus infection at upper respiratory tract of human results in several 
symptoms, such as fever, chills, muscle aches, fatigue and headaches.  Through 
human history, influenza virus caused epidemics and severe pandemics at 
several times. 
As mentioned above, many influenza pandemics occurred in human 
history.  However, since 19th century, reports and data about influenza pandemics 
have been more comprehensive and reliable.  In 1918, Spanish influenza, which 
killed 40-50 million people, is the first of the two pandemics involving H1N1 
influenza virus (the second being the 2009 influenza pandemic) (Taubenberger et 
al, 2006).  Furthermore, in 1957-1958 and 2009, two influenza pandemics spread 
in southern China killed about 4 million people (reported by WHO, 2005), and 
also a recent outbreak of human infections with a new avian influenza A (H7N9) 
virus, which has involved 132 patients, including 37 deaths in 2013 (reported by 
WHO, 2013). 
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 1-2. Significance of viral research 
Seasonal influenza virus infections in humans cause annual epidemics, 
leading to millions of human infections worldwide and having significant health 
and economic burdens; influenza pandemics can also have devastating effects 
globally, resulting in millions of deaths.  Within one year, this virus spread to all 
the world and caused >18,000 confirmed deaths (Medina et al, 2011).  Thus, this 
virus research plays an important role for protection of public health as well as 
economic developments globally.  Also important to development of new 
vaccines and anti-influenza drugs.   
                            
2. Purpose and summary of this study 
PB1 functions as a catalytic subunit of RNA polymerase and contains the 
highly conserved motifs of RNA-dependent RNA polymerases.  Putative 
nucleotide-binding sites have been mapped adjacent to this region.  PB1 also 
binds to vRNA and cRNA, and the putative promoter binding sites have been 
mapped.  PA and PB2 interact with the N-terminal and C-terminal regions of PB1, 
respectively.  Thus, some structures and functions of PB1 have been clarified. 
However, the relationship between the structures and functions are not clarified. 
Therefore, to clarify this relationship based on its structure, I started the 
functional analysis of PB1 subunit using mutant viruses by determining the 
replicational and transcriptional activities and using ribavirin by isolation of 
ribavirin-resistant PB1 mutants.   
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3. Abbreviations 
a a    amino acid 
CHX   cycloheximide 
cRNA   complementary RNA 
DMEM  Dulbecco’s modified Eagle’s medium 
FBS   Fetal bovine serum 
HA   hemagglutinin 
hpi    hour(s) post infection 
hpt   hour(s) post transfection 
M1   matrix protein 1 
M2   matrix protein 2 
MEM   Minimum essential medium 
MOI   multiplicity of infection 
NA   neuraminidase 
NP   nucleoprotein 
NS1   nonstructural protein 1 
NS2   nonstructural protein 2 
NLS    nuclear localization signal 
PA   polymerase acidic protein 
PB1   polymerase basic protein 1 
PB2   polymerase basic protein 2 
RdRp   RNA-dependent RNA polymerase  
RNP   ribonucleoprotein 
 7 
rpm   round per minute 
PFU   plaque formation unit 
Pol II   DNA-dependent RNA polymerase II 
vRNA   viral RNA, virus genome 
vRNP   viral ribonucleoprotein 
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4. General remarks of influenza virus 
 4-1. Structure of influenza virus genome and viral proteins 
 Influenza virus belonging to family of Orthomyxoviridae can range from 
spherical shape with a particle size about 80 to 120 nm in a diameter (Fig. 1A).  
Influenza viruses can be categorized into 3 types: A, B and C.  Influenza A and B 
viral genomes consist of eight segmented - and single-stranded RNAs of 
negative polarity (vRNA), while influenza C virus genome consists of seven 
segmented - and single-stranded RNAs of negative polarity.  The three largest 
RNA segments (segment 1, 2, and 3) encode the three viral RNA-dependent 
RNA polymerase (RdRp) proteins: polymerase basic protein 2 (PB2), polymerase 
basic protein 1 (PB1), and polymerase acidic protein (PA), respectively.  The 
RNA segment for PB1 also encodes non-structural proteins, PB1-F2,  a 
proapoptotic virulence factor (Wise et al, 2009), and PB1-N40, its function is 
unknown.  Except for PB1, these two proteins are not essential for replication.  
Segment 4, 5, and 6 encode hemagglutinin (HA), nucleoprotein (NP), and 
neuraminidase (NA), respectively.  Segment 7 encodes the M1 matrix protein and 
the M2 ion-channel protein, segment 8 encodes two nonstructural proteins, NS1A 
and NS2/NEP (Kalyan Das et al, 2010).  The influenza A, B, and C viruses can 
be distinguished on the basis of antigenic differences between their NP and M 
proteins.  Influenza A viruses are further divided into subtypes based on the 
antigenic nature of their HA and NA glycoproteins.  These spikes are of two 
types: HA is rod-shaped spikes and NA is mushroom-shaped spikes.  The ratio of 
HA to NA varies but is usually 4:1 to 5:1.  The viral matrix protein, M1, is thought 
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to underlie the lipid bilayer and to associate with the replicated virus genome.  
M1 is the most abundant virion protein.  The HA spike glycoprotein is a 
homotrimer of noncovalently linked monomers.  Each HA polypeptide chain (H3 
subtype) consists of an ectodomain of 512 residues, a carboxyl-terminal proximal 
transmembrane domain of 27 residues, and a cytoplasmic tail of 10 residues.  HA 
exists either in an uncleaved precursor form (HA0) or in a cleaved form 
consisting of two disulfide-linked chains (HA1, and HA2).  The NA integral 
membrane protein is the second subtype-specific glycoprotein of influenza A and 
B viruses.  The NA is a homotetramer containing a head domain that is 
enzymatically active and a stalk region that is attached to the membrane.  NA is 
important for removing sialic acids, which function as a viral receptor, from 
glycoproteins expressing on host cell variation.  In addition, influenza pandemics 
are being caused by the appearance of an emerging strain containing amino acid 
changes in HA and NA surface proteins.  These changes partially overcome pre-
existing immunity in humans, and these new strains are largely responsible for 
seasonal influenza epidemics.  The matrix protein M1, which lies inside the lipid 
envelope and constitutes the most abundant polypeptide in the virion, and the M2 
protein, which is a minor component of virions and has an ion chanel activity.  
The NS1 protein is expressed in large amounts in influenza virus-infected cells, 
but it has not been detected in virions, hence the designation NS for non-
structural.  NS1 is found in infected cells in the nucleus and is associated with 
polysomes.  The NLS (nuclear localization signal) within NS1 has been mapped, 
and it has been found that the protein contains two separate signals (residues 34 
 10 
to 38 and within residues 203 to 237).  The NS1 protein also contains a nuclear 
export signal (NES), a short leucine-rich sequence that mediates the nuclear 
export of proteins.  The NS1 NES has been mapped to residues 138 to 147.  The 
NS2 protein, originally thought to be non-structural, is now known to exist in 
virions and to form an association with the M1 protein.  The subcellular 
localization of NS2 has been indicated to be nuclear and cytoplasmic (Knipe et al, 
2001).  The NES on the N-terminus of NS2 is recognized by chromosomal 
maintenance 1 (CRM1), but this CRM1 binds with RanGTP to an unknown site.  
The C-terminal hairpin of NS2 in turn associates with the N-terminal nuclear 
localization signal of the viral matrix protein M1, and the M1 protein binds to the 
vRNP through a C-terminal interaction with NP.  These interactions have led to 
the description of the vRNP nuclear export complex as a daisy chain CRM1-
RanGTP-NS2-M1-vRNP (Paterson, 2012). 
The N-terminal region of PB1 interacts with the C-terminal region of PA 
(Ghanem et al, 2007; Gonzalez et al, 1996; Ohtsu et al, 2002; Perez et al, 1995; 
Toyoda, et al, 1996; Zurcher et al, 1996), and the crystal structure of this 
interaction has been resolved (He et al, 2008; Obayashi et al, 2008).   The C-
terminal region of PB1 between amino acid (a.a.) positions 678-757 interacts with 
the N-terminal region of PB2 (Gozalez et al, 1996; Ohtsu et al, 2002; Poole et al, 
1981; Toyoda et al, 1996), and this interaction was analyzed by crystallography 
(Sugiyama et al, 2009).  PB1 contains the motifs highly conserved among RNA-
dependent RNA polymerases (Biswas et al, 1994).  There are two putative 
nucleotide-binding sites between a.a. positions 179-297 and between a.a. 
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positions 458-519 (Asano et al, 1997; Kolpashchikov et al, 2004).  Moreover, the 
N-terminal (a.a. positions 1-83) and C-terminal (a.a. positions 494-757) regions 
of PB1 are suggested to bind to the vRNA promoter (Gozalez et al, 1999a).  In 
addition, it is reported that the vRNA binding site of PB1 is located at the a.a. 
positions 249-254, and phenylalanines at the positions 251 and 254 are essential 
for this binding (Li et al, 1998).  It is also reported that the N-terminal region (a.a. 
positions 1-139) and a region between a.a. positions 267 and 493 bind to the 
cRNA promoter (Gozalez et al, 1999b).  Recently, novel proteins, PB1-F2 and 
PB1-N40, produced by splicing were identified (Wise et al, 2009).  It is suggested 
that these are involved in the virulence, but not essential for the replication. 
 
 4-2. Structure and function of RNP complex 
Each segment of influenza virus is encapsidated by nucleoprotein (NP) and 
associated with viral RNA polymerases to form viral ribonucleoprotein (vRNP) 
complexes.  The viral RNA polymerase is composed of one molecule each of 
three viral proteins, PB1, PB2, and PA.  PB1 functions as a catalytic subunit and 
assembly core of the viral RNA polymerase (Biswas et al, 1996; Gozalez et al, 
1996; Ohtsu et al, 2002; Zurcher et al, 1996).  PA is genetically found to be 
involved in the replication process and the polymerase assembly (Kawaguchi et 
al, 2005) and have the endonuclease activity (Dias et al, 2009; Fodor et al, 2002; 
Hara et al, 2006; Yuan et al, 2009).  PB2 is responsible for recognition and 
binding the cap structure (Fechter et al, 2003; Guilliary et al, 2008; Li et al, 2001; 
Plotch et al, 1981; Wakai et al, 2011).  The vRNP complex is a basic unit for both 
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transcription and replication (Nagata et al, 2008) (Fig. 2).  Both vRNA and cRNA 
promoters form a specific secondary structure, depicted as “corkscrew model”.  
This model structure includes the partial duplex regions formed by the 5’- and 3’-
terminal sequences of vRNA and cRNA that are partially complementary to each 
other.  These duplexes are conserved in all eight segments and act as cis-acting 
elements for the viral RNA synthesis (Nagata et al, 2008). 
 
 4-3. Transcription and replication of influenza virus genome 
   Replication and transcription of the viral RNA genome occur in the nucleus.  
Transcription of the viral genome is initiated using as a primer the oligonucleotide 
containing the cap-1 structure derived from cellular pre mRNAs.  The capped 
oligonucleotide is generated through recognition of the cap structure by PB2 
(Nagata et al, 2008) and endonucleolytic cleavage by PA (Dias et al, 2009; Fodor 
et al, 2002; Hara et al, 2006; Yuan et al, 2009).  The elongation of the mRNA 
chain proceeds until the viral polymerase reaches a polyadenylation signal, 
which consists of 5-7 uridine residues located near the 5’- terminus of the vRNA.  
The viral polymerase generates a poly (A) tail at the end of the viral mRNA by 
stuttering and slipping between the template and nascent elongating RNA chain.  
It is shown by mutants in the promoter of vRNA that the cleavage of the cap 
structure and the polyadenylation by the viral polymerase are regulated through 
the promoter structure.  In contrast, the genome replication is primer-independent 
and generates full-length cRNA from vRNA, and progeny vRNA is in turn copied 
from the cRNA (Fig. 2) (Nagata et al, 2008).  
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5. Materials and Methods 
 5-1. Plasmids 
To construct plasmids from which human DNA-dependent RNA 
polymerase I (Pol I) transcribes mutated vRNAs, I amplified fragments containing 
mutated segment 2 by PCR using a plasmid containing wild type WSN segments 
in pHH21 vector (Neumann et al, 1999) as a template with sets of 
phosphorylated primers (see Table 1).  The amplified PCR products containing 
5’-PO4 and 3’-OH were self-ligated using ligation high (TOYOBO).  Sequences of 
plasmids containing these mutated segment 2 were confirmed by sequencing 
with Dyenamic ET sequencing system (ABI).   
 
 5-2. Cell culture 
  Monolayer cultures of 293T and MDCK cells were maintained at 37oC in 
Dulbecco’s Modified Eagle Medium (DMEM) and minimal essential medium 
(MEM) (Nissui), respectively, supplemented with 10% fetal bovine serum 
(Bovogen).  Influenza virus strain A/WSN/33 (A/WSN/33) was prepared as 
previously described (Kawaguchi et al, 2005).   
 
 5-3. Antibodies  
Rat polyclonal antibodies against PB1, PB2, and PA were prepared as 
described previously (Kawaguchi et al, 2005).  Rabbit polyclonal antibody against 
PB2 was prepared as described previously (Naito et al, 2007).  Mouse 
monoclonal antibody against β-tubulin was purchased from Sigma.  
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 5-4. Generation of recombinant viruses 
  To generate recombinant viruses, reverse genetics system was used as 
described previously (Neumann et al, 1999).  Briefly, 293T cells were transfected 
with 4 plasmids for expressing viral proteins (PB1, PB2, PA, and NP) and 8 
plasmids for expressing a full set of the viral RNA genome.  After incubation at 
37oC with 5% CO2 for 48 hours post transfection (hpt), aliquots of cell culture 
supernatants were used for virus amplification in MDCK cells.  At 48 hours post 
infection (hpi) at 37oC with 5% CO2, culture fluid was collected, and the virus titer 
of these recombinant viruses was determined by plaque assays. 
 
 5-5. Plaque assay 
The plaque assay was performed in 6-well tissue culture plates. The 
MDCK cells were seeded at 1 x 106 cells per well in (Minimum essential Medium 
Eagle) (Sigma) with 10% FBS before carrying the experiment.  After 12h, 50 PFU 
of influenza virus (WSN) were added to the cell monolayer and the plates 
incubated at 37oC for 1h with 5% CO2 before removal of unbound viral particles 
by aspiration. The cell monolayer was washed once with MEM (Nissui, Tokyo, 
Japan) just before being overlaid with 1.6% low melting agarose (final 
concentration, 0.8%) (Type I, Sigma) was mixed with an equal volume of 2x 
maintenance medium (final concentration, 1x) with or without supplementing 
compounds, the mixture was maintained at 40oC and dispensed in the wells (3 
ml/well). The plates were incubated for 48h at 37oC with 5% CO2. After 48h, the 
wells were fixed with ethanol and acetic acid (ratio 1: 1), the agarose gel had 
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been removed before the monolayers were stained with 0.5% Amido Black 
solution (0.5 g amido black, acetic acid 10 ml, ethanol 45 ml, and up water to 100 
ml)  and the plaques were counted. 
 
 5-6. RNA analysis  
MDCK cells were infected with recombinant viruses at the multiplicity of 
infection (MOI) of 2.5, and incubated at 37oC with 5% CO2.  At 3, 6, and 9 hpi, 
total RNAs were isolated by the acid guanidine-phenol-chloroform (AGPC) 
method. 
 
 5-7. Quantitative RT-PCR (qRT-PCR) 
  To measure the accumulation levels of viral mRNA, cRNA, and vRNA, 
quantitative RT-PCR was performed.  Total RNAs were subjected to reverse 
transcription using ReverTraAce (TOYOBO) with either (i) oligo (dT)20 for 
synthesizing cDNA from viral mRNA, (ii) 5’-
AGTAGAAACAAGGGTATTTTTCTTTA-3’, which is complementary to the 3’ 
portion of segment 5 cRNA between nucleotide sequence positions 1540 and 
1565 for synthesizing cDNA from cRNA, or (iii) 5’-
GACGATGCAACGGCTGGTCTG-3’, which corresponds to segment 5 cRNA 
between nucleotide sequence positions 424 and 444 for synthesizing cDNA form 
vRNA.  The synthesized single-stranded cDNAs were subjected to real-time 
quantitative PCR analysis (Thermal Cycler Dice real-time system TP800; 
TaKaRa) with SYBR Premix Ex Taq (TaKaRa) and a set of specific primers, 5’-
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GACGATGCAACGGCTGGTCTG-3’, which corresponds to segment 5 cDNA 
between nucleotide sequence positions 424 and 444, and 5’-
AGCATTGTTCCAACTCCTTT-3’, which is complementary to segment 5 cDNA 
between nucleotide sequence positions 595 and 614.  The levels of these RNAs 
were normalized by the amount of cellular β-actin mRNA measured using specific 
primers 5’-ATGGGTCAGAAGGATTCCTATGT-3’, which corresponds to β-actin 
cDNA between nucleotide sequence positions 1363 and 1385, and 5’-
GGTCATCTTCTCGCGGTT-3’, which is complementary to the β-actin cDNA 
between nucleotide sequence positions 1567 and 1584. Experiments are carried 
out three independent with standard deviations, and the level of significance was 
determined by Student’s t  test (unpaired).  
 
 5-8. Primary transcription activity of mutant viruses 
  MDCK cells were infected with mutant viruses at MOI of 2.5 and incubated 
at 37oC with 5% CO2 in the presence of 100 μg/ml of cycloheximide (CHX).  At 9 
hpi, the accumulation levels of viral mRNA and vRNA were measured by qRT-
PCR as described above.  Experiments are carried out three independent with 
standard deviations, and the level of significance was determined by Student’s t  
test (unpaired).   
 
 5-9. Immunoprecipitation   
MDCK cells were infected with recombinant viruses at MOI of 1.  At 7 hpi, 
cells were lysed by sonication in a buffer A containing 50 mM Tris-HCl (pH 7.9), 
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100 mM NaCl, 30 mM KCl, and 0.1% Nonidet P-40.  The  lysates were subjected 
to centrifugation at 16,000 x g, at 4oC for 10 min.  RNA polymerase complex in 
the supernatant fraction was subjected to immunoprecipitation with rabbit anti-
PB2 antibody bound to protein A sepharose beads (GE Healthcare) at 4oC, for 2 
h.  The beads were washed 4 times with buffer A and proteins bound to the 
beads were eluted by boiling them in an SDS-PAGE loading buffer and were 
subjected to 7.5% SDS-PAGE.  To detect each viral RNA polymerase subunit, rat 
anti-PB1, PB2, and PA antibodies were used for western blotting analysis, 
respectively.   
 
 5-10. PB1 random mutagenesis 
For construction of a mammalian expression vector for PB1 containing 
random mutations, I used a PCR-based cloning strategy with MnCl2.  cDNA 
corresponding to the full-length of PB1 was amplifed with specific primers 5’-
CCCCAAGCTTGCCGCCACCATGGATGTCAATCCGACCTT-3’ and 5’-
CATGCGGCCGCCTATTTTTGCCGTCTGAGCTCTT-3’.  The PCR product was 
then cloned into the Hind III and Not I sites of pEGFP-N1 and replaced with 
EGFP gene with mutated PB1 cDNA.  The composition of the plasmid library was 
confirmed by sequencing using specific primer 5’-
GGAAGGCTCATAGACTTCCTTA-3’, which is corresponding to the position from 
560 to 1050 nucleotide in segment 2.  The plasmid library was then used to 
analyze the influenza virus RNA polymerase activity in mini-replicon assay 
system. 
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 5-11. Mini-replicon assay system   
293T cells  were transfected with plasmids for the expression of viral 
proteins, PB1 (wt or mutated-type), PB2, PA, and NP, and a plasmid for the 
expression of artificial influenza virus genome containing either EGFP gene (for 
screening) or the firely luciferase gene (for luciferase assay) of negative polarity, 
which is synthesized in cells by the human DNA-dependent RNA polymerase I 
[pol I]) (Turan et al, 2004).  mRNAs containing EGFP and luciferase genes are 
transcibed in a viral RNA polymerase-dependent manner.  For the screening, 
ribavirin was added (0 or 75 µM) after 3 hours post transfection (hpt) and the 
fluorescence of EGFP was observed at 15 hpt.  For luciferase assay, either 
ribavirin (Sigma) was added in the medium at various concentrations after 3 hpt, 
and incubated at 37°C for 15 h, or after 12 hpt, different concentrations of 
methotrexate (MTX) was added, and incubated at 37°C for 10 h, and then the 
luciferase activity was determined using commercially available reagents 
(Promega) according to the manufacturer’s protocol.  The relative luminescence 
intensity was measured with a luminometer for 20 sec.  A plasmid for the 
expression of Renilla luciferase driven by the simian virus 40 (SV40) promoter 
was used as an internal control for the dual-luciferase assay.  As a negative 
control, 293T cells were transfected with the same plasmids, except for the 
omission of the PB1 expression plasmid.   
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Chapter II. The N-terminal region of influenza virus polymerase PB1 
adjacent to the PA binding site is involved in replication but not 
transcription of the viral genome 
 
1.  Purpose 
In this study, I have focused my study on the N-terminal region (a.a. 
residues 1-83) of the putative vRNA and cRNA promoter binding sites of PB1.   
An alignment analysis of the amino acid sequence has revealved that the a.a. 
positions 1-50 was highly conserved between influenza A and B viruses, but the 
amino acid positions 16, 27, and 44 differ between two viruses.  To identify the 
functional importance of these positions in replication and transcription of the 
viral genome, I generated viruses containing mutations at these positions by 
reverse genetics, and determined the replicational and transcriptional activities of 
these mutants.   
 
2. Results 
 2-1.  RNA synthesis of influenza A mutant viruses containing influenza B 
virus-type amino acid signatures 
The promoter sequence of influenza A virus genome forms panhandle like 
structure (Fodor et al, 1994).  These stem-loop structures are important for the 
interaction of viral polymerase (Leahy et al, 2001).  When viral polymerase 
interacts with the promoter element, it has been reported that the RNA synthesis 
activity and capping activity are significantly stimulated (Leahy et al, 2002), 
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suggesting that the enzymatic activities of viral polymerase are regulated by the 
interaction with promoter sequence.  But, the detail of regulatory mechanisms is 
still unclear.  Further, influenza B promoter also forms panhandle like structure 
similar to that of influenza A virus.  However, influenza A polymerase weakly 
recognize the influenza B promoter (Muster et al, 1991).  Thus, it is possible that 
by comparing the amino acid sequence of the influenza A and B in the promoter 
binding site, we can find important residues for the promoter recognition and its 
viral polymerase activity. 
The C-terminal region of PB1 contains a putative vRNA promoter binding 
site, while the N-terminal region of PB1 (1-83 a.a.) contains both putative vRNA 
and cRNA promoter binding sites and PA binding site (1-15 a.a.) (Fig. 3A).  
However, except for the PA binding site, the crystal structure of which was 
determined (He et al, 2008; Obayashi et al, 2008), the function of N-terminal 
region of PB1 was poorly understood.  The a.a. positions from 1 to 50 of PB1 
was highly conserved (85%) between influenza A and B viruses but that from 51 
to 757 of PB1 was not highly conserved (50-60%).  The region between a.a. 
positions 1 and 50 are highly conserved between influenza A and B viruses, a.a. 
positions 40 and 48 containing Met and Gln of influenza A and Ile and Glu of 
influenza B have the same properties (nonpolar and polar), respectivly, except for 
the PA binding site, amino acids at positions 16, 27, and 44 are different between 
these viruses (Fig. 3B).  To elucidate the functional importance of these amino 
acids for viral RNA synthesis, I generated influenza A viruses containing Ala at 
the a.a. position 16, Val at the a.a. position 27, and Ile at the a.a. position 44 by 
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reverse genetics.  These mutated viruses are designated N16A, D27V, and N44I, 
where capital letters at the first position, numbers at the second position, and 
capital letters at the third position indicate wild type a.a., a.a. position, and 
replaced a.a., respectively.  I examined the RNA polymerase activity by 
measuring the accumulation levels of viral mRNA, cRNA, and vRNA at 3 and 6 
(Fig. 4), and 9 hpi (Fig. 5) by quantitative reverse transcription-PCR (qRT-PCR).  
At 9 hpi, the levels of all three type RNAs from D27V were increased compared 
with those from wild type and N16A virus ( 2.5-fold), while those from N44I were 
significantly decreased (about 3-fold) (Fig. 5).  Based on the result that these 
mutations affect the RNA synthesis activity of viral mRNA, cRNA, and vRNA 
equally, there could be two possibilities: (i) amino acids at the positions 27 and 
44 affect cRNA/mRNA synthesis from vRNA through recognition of the promoter 
on vRNA, but do not affect vRNA synthesis from cRNA through recognition of the 
promoter on cRNA, or (ii) these mutations affect independently the synthesis of 
mRNA, cRNA, and vRNA, but the sum of effects leads similar outputs in the 
synthesis of mRNA, cRNA, and vRNA. 
 To elucidate whether these mutations affect viral replication (cRNA and 
vRNA synthesis) and/or transcription (viral mRNA synthesis) activities, I 
measured the primary transcription activity (Fig. 6A).  MDCK cells were infected 
with mutant viruses and then incubated with the medium containing 
cycloheximide (CHX), a potent inhibitor of protein synthesis.  In the presence of 
CHX, newly synthesized RNA polymerases are not supplied, and the replication 
process does not occur (Kawaguchi et al, 2005).  I utilized this method to 
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measure the primary transcription activity that depends just only on incoming 
vRNP and is not affected by the replication process.  At 9 hpi in the presence of 
CHX, the levels of viral mRNA and vRNA were measured by qRT-PCR, and the 
transcription activity was represented as a ratio of viral mRNA/vRNA (Fig. 6A).  
This result shows that the transcription activity is not affected by these mutations, 
and thereby strongly suggest that these mutations affect the replication activity.  If 
it is hypothesized that the recognition mechanism of the promoter on vRNA for 
mRNA synthesis would not be different from that for cRNA synthesis, the 
replication process from cRNA to vRNA could be affected by these mutations.  
This also leads to the possibility that vRNA and cRNA promoter binding sites may 
be seperately affected by mutants.   
 
 2-2.  Uncharged amino acid at the a.a. position 16  is required  
To know whether the charateristics for the viral polymerase activity of the 
amino acid at the position 16 affect viral RNA synthesis or not, I generated N16D 
(D: position 27) and N16Q (structure of Q is close to that N), in addition to N16A 
(Fig. 7 and Fig. 8).  At 9 hpi, the amount of each viral RNA of N16D was 
decreased compared with that of wild-type (3.5 fold), while those of N16Q and 
N16A were not significantly changed compared with wild type (Fig. 8).  
Negatively charged amino acid may decrease the viral RNA polymerase activity.   
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 2-3.  Uncharged amino acid at position 27 enhances the RNA synthesis 
activity   
The amino acid position 27 of PB1 is aspartate, and aspartate is highly 
conserved among influenza A viruses, except for an H4N8 strain isolated from 
least sandpiper that contains asparagine (GenBank: ACI90144.1).  I generated 
D27E and D27N in addition to D27V (Fig. 9 and Fig. 10).  At 9 hpi, the levels of 
mRNA, cRNA, and vRNA of D27N and D27V were increased significantly (about 
2 to 2.5 fold) compared with those of wild-type and D27E (Fig. 10).  These results 
suggest that uncharged residues at amino acids  position 27 may enhance the 
viral RNA synthesis activity.    
 
 2-4.  Hydrophilic residues at amino acid position 44 is important for the 
viral RNA synthesis activity   
The amino acid substitution from asparagine to isoleucine at the a.a. 
position 44 reduced the viral polymerase activity.  To clarify the importance of the 
amino acid position 44, I additionally generated N44D and N44Q viruses in 
addition to N44I and examined the viral RNA synthesis activity (Fig. 11 and Fig. 
12).  At 9 hpi, the synthesis level of each viral RNA of N44I was decreased largely, 
while the amounts of mRNA and cRNA of N44D and N44Q were similar to those 
of wild type (Fig. 12A and 12B).  In addition, the amount of vRNA of N44Q was 
more than that of wild type (about 2 fold) (Fig. 12C).  These results suggest that 
the amino acid residue at the a.a. position 44 would be a water-soluble 
characteristic, and especially glutamine at this position stimulates the vRNA 
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synthesis.  It is assumed that asparagine and glutamine at this position have a 
similar effect/function on the viral RNA synthesis, although the N44Q polymerase 
may have some cooperative property in RNA binding, subunit interaction, and/or 
etc.  This cooperative property could appear as a function of infection time, 
namely, the involvement of increasing amounts of viral proteins and/or viral RNAs.   
 
3.  Discussion 
In this report, to elucidate the function of a putative promoter binding 
region of PB1, I focused on the N-terminal region of PB1 between a.a. positions 
of 1-50 (Fig. 3).  I have studied on three positions, i. e., a.a. positions 16, 27, and 
44, which are not conserved between influenza A and B viruses.  The RNA 
synthesis activity of D27V containing influenza B virus-type a.a. was enhanced 
compared with that of wild type virus, while that of N44I was decreased (Fig. 5).  
Based on these, I carried out further mutational analyses.  The N44I showed the 
decreased level of RNA synthesis in three types of viral RNAs, while N44D 
showed the viral RNA synthesis activity similar to wild type virus.  Interestingly, N-
>Q mutation at the a.a. position 44 increased vRNA synthesis with little effect on 
viral mRNA and cRNA synthesis.  Asparagine, glutamine, and aspartic acid are 
polar or charged, whereas isoleucine is uncharged.  These results suggest that a 
hydrophilic moiety of amino acids at the position 44 may be important.  It is also 
possible that the length of side chain group of glutamine may stimulate the cRNA 
promoter binding and increase the vRNA synthesis activity. 
On the a.a. position 27 (Fig. 10), D->V and D->N mutations increased the 
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viral RNA synthesis, while D->E mutation gave no effects.  Aspartic acid and 
glutamic acid are acidic, but asparagine and valine are uncharged amino acids.  
Furthermore, when the amounts of viral RNAs of D27V were analyzed at various 
moi (0.5, 2.5, 10, and 25), those of D27V were increased (Fig. 13).  Although 
uncharged amino acid at this position enhances the viral RNA synthesis, 
molecular evolution has selected negatively charged amino acids.  Therefore, it 
is assumed that charged amino acids at this position, even with low efficiency for 
the replication, are needed for PB1.  Recently, mutational analyses showed that 
the sequences surrounding the PB1 AUG codon are multifunctional, and contain 
overlapping signals for translation initiation and for segment specific packaging 
(Wise et al, 2011).  It is assumed that there is some regulatory coupling between 
replication and packaging and the a.a. position 27 has a role in this hypothetical 
mechanism.  
To confirm whether these mutations affect replication and/or transcription, I 
analyzed the primary transcription activity in the presence of cycloheximide (Fig. 
6), which is not affected by replication processes.  The transcription activity of 
these mutants was similar to that of wild type.  This results indicate that these 
mutations affected the replication activity but not the transcription activity.   
 These a.a. positions are present within putative vRNA and cRNA 
promoter binding sites (Gonzalez et al, 1999a; Gonzalez et al, 1999b), and the 
PB1-RNA interaction could be affected by the presence of PA.  PB2 subunit 
participates in the recognition of vRNA but not cRNA (Gonzalez et al, 1999b).  
Moreover, as these amino acids are close to the PA binding site, I examined 
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whether these mutations affect the assembly of the polymerase (Fig. 14).  The 
assembly of PB1 with PA and PB2 was not affected by these mutations.  Taken 
altogether, it is quite likely that amino acid residues at the a.a. positions 27 and 
44 are involved in the viral genome replication, possibly via the cRNA promoter 
recognition with little effects on the transcription activity and the assembly of the 
RNA polymerase complex. 
 All eight genomic RNA segments of influenza A virus have 12 and 13 
conserved 5’- and 3’-terminal nucleotides, respectively.  This conservation, 
together with two or three segment-specific nucleotides show inverted partial 
complementarity.  Interaction between the 5’- and 3’-end, through base pairing, is 
required for promoter activity (Crow et al, 2004).  Both vRNA and cRNA 
promoters form a specific secondary structure, depicted as “corkscrew model” 
(Nagata et al, 2008).  The cRNA and vRNA promoter structures are different 
substantially (Park et al, 2003; Tchatalbachev et al, 2001).  Recognition of the 
vRNA promoter depends on the 5’-arm of the promoter (Flick et al, 1996; 
Gonzalez et al, 199a; Lee et al, 2002; Tiley et al, 1994).  In contrast, binding of 
the RNA polymerase to the 3’-arm of the vRNA promoter is weak, but this binding 
is highly improved by the presence of the 5’-arm (Gozalez et al, 1999a; Jung et al, 
2006; Tiley et al, 1994).  Furthermore, it is suggested that, in order for the viral 
template RNA to be recognized by the viral polymerase, this RNA has to be 
encapsidated by the NP (Parvin et al, 1989).  Recognition of the cRNA promoter 
by the polymerase has been shown by the in vitro binding of the PB1 subunit with 
the 5’- and 3’-arms of the cRNA promoter (Gonzalez et al, 1999b).  The structural 
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differences may also account for the preferential encapsidation of vRNPs versus 
cRNPs (Tchatalbachev et al, 2001).  Flexibility within the two uridines of the 
internal loop of the cRNA promoter required for protein binding in the cRNP 
complex (Park et al, 2003).  Biochemical studies have shown that conformational 
changes in PB1 of the influenza A virus RNA polymerase lead to the interaction 
with either vRNA or cRNA  (Gonzalez et al, 1999b).  Based on previous reports 
and our findings, the a.a. positions 27 and 44 may affect the PB1 structure, 
resulting in affecting PB1 binding activity to the 3’-arm of the cRNA promoter.  
Thus, I would propose that these positions in PB1 is important for the replication 
activity by recognizing the cRNA promoter. 
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Chapter III. Asparagine at position 27 in PB1 is responsible for ribavirin 
resistance 
 
1.  Purpose 
Ribavirin (1-β-D-ribofusanosyl-1,2,4-triazole-3-carboxamide, also known as 
Virazole) is a synthetic purine nucleoside analogue first synthesized by Sidwell 
and colleagues in 1972 (Sidwell et al, 1972).  It is phosphorylated by a cellular 
adenosine kinase into ribavirin monophosphate, diphosphate, and triphosphate 
(RMP, RDP, and RTP respectively) (Dixit et al, 2006; Feld et al, 2005) and has 
been shown to exhibit the antiviral activity against many distinct viruses in vitro 
as well as in vivo via indirect (inosine monophosphate dehydrogenase inhibition, 
immunomodulatory effects) and direct (interference with RNA capping, 
polymerase inhibition, lethal mutagenesis) mechanisms (Graci et al, 2006).  
Ribavirin inhibits viral RNA polymerases such as those of influenza virus 
(Eriksson et al, 1977), VSV (vesicular stomatitis virus) (Tolzis et al, 1988), La 
Crosse virus (Cassidy et al, 1989), Reo virus (Rankin et al, 1989), Hantaan virus 
(Sun et al, 2007)  FMDV (Foot and Mouth Disease Virus) (Gu et al, 2006), human 
immunodeficiency virus (Fernandez et al, 1990), West Nile virus (Jordan et al, 
2000), LCMV (lymphocytic choriomeningitis virus) (Moreno et al, 2011), Andes 
virus (Safronetz et al, 2011), and HCV (Hepatitis virus) replication (Magg et al, 
2001).  While, ribavirin does not inhibit RNA polymerase I, RNA polymerase II, or 
poly (A) polymerase (Muller et al, 1977). 
    Ribavirin is known to increase the error in the viral genome during viral 
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replication by being incorporated in place of guanosine in nascent viral RNA 
strands (Dixit et al, 2006).  The in vitro incorporation studies suggested that 
ribavirin should induce transition mutations. This incorporation will induce G→A 
transition if incorporated into genomic RNA (Cameron et al, 2001; Crotty et al, 
2000), ribavirin also causes chain termination in HCV and polio viruses (Maag et 
al, 2001).  Since the influenza virus RNA polymerase replicates its genome with a 
low fidelity (Aggarwal et al, 2010), in the presence of ribavirin, the replication 
defect and error catastrophe are found by mis-incorporation of the ribavirin 
(Crotty et al, 2001; Gu et al, 2006; Severson et al, 2003).   
In this study, to determine the catalytic active site of PB1, resistant mutant 
of PB1 against ribavirin was identified.  Ribavirin inhibits viral RNA synthesis as 
an analog of both adenine and guanine, and causes mutations in viral genome 
influenza viruses.  Isolation of the ribavirin-resistant PB1 mutants are useful to 
know the mechanism of nucleotide recognition by the viral RNA polymerase. 
 
2.  Results  
 2-1. Screening of ribavirin-resistant PB1 mutant   
To make PB1 mutant library, random mutagenesis was examined by PCR 
with 0.1 mM of Mn2+ and 1.5 mM of Mg2+ as described in materials and methods.  
To know the mutation rate of this library, I transformed the library into E.coli DH5α 
high competent cells and got 3 x 104 colonies.  To evaluate the mutation rate, 
plasmids were isolated from 20 colonies and sequenced at the position from 560-
1055 of segment 2.  The results of sequencing showed that mutation was 
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introduced in 4.7 mutation/ 2274 nucleotides of segment 2 (approximately 1-2 
aa/PB1).  With this result, I started screening ribavirin-resistant PB1 from the 
mutant library (Fig. 15A).  At first, this library was divided into 10 groups, and 
mini-replicon assay was performed in the presence of ribavirin (Fig. 15A and B).  
The fluorescence of EGFP was checked at 15 hpt.  Based on the fluorescence of 
each group, I chose 1 group which showed  the highest fluorescence among 10 
groups followed by dividing into additional 10 groups and performing mini-
replicon assay again.  After 5 time repetitions of this step, D27N mutant of PB1 
was isolated (Fig. 16A).   
 
 2-2. Characterization of D27N mutant   
To confirm the ribavirin resistance, I carried out the mini-replicon assay with 
EGFP reporter gene (Fig. 16B).  The ratio of EGFP fluorescence on ribavirin-
treated cells of D27N mutant (69%) was higher than that of wild-type (24%).  This 
result indicates that D27N mutation in PB1 contributes to ribavirin resistance.  To 
quantitatively measure the viral polymerase activity, luciferase assay was carried 
out in the presence of various concentrations of ribavirin.  The luciferase activity 
of D27N mutant was higher than that of wild type (Fig. 16C). IC50 of ribavirin for  
D27N mutant was about 18 µM, while that for wild-type was around 10 µM (Fig. 
16C).  Furthermore, the expression level of PB1 was confirmed by western blot 
analysis.  The expression level of D27N mutant PB1 were similar to that of wild-
type and not affected by the addition of ribavirin (Fig. 16D).  To further analyze 
this mutant, we used methotrexate (MTX).  MTX is an inhibitor for purine 
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biosynthesis, resulting in decrease of purine concentration in cell.  The mini-
replicon assays were performed in the presence of various concentration of MTX.  
The viral polymerase activity of D27N was significantly remained even in the 
presence of MTX compared with that of wild type (Fig. 17). 
 
3. Discussion 
PB1 functions as a catalytic subunit of viral RNA polymerase (Biswas et al, 
1996; Gozalez et al, 1996; Ohtsu et al, 2002; Zurcher et al, 1996) and contains 
the highly conserved motifs of RNA-dependent RNA polymerases (Biswas et al, 
1994). Putative nucleotide-binding sites have been mapped adjacent to this 
region (Asano et al, 1997; Kolpashchikov et al, 2004).  PB1 also binds to vRNA 
and cRNA, and the putative promoter binding sites have been mapped (Gozalez 
et al, 1999a). PA and PB2 interact with the N-terminal and C-terminal regions of 
PB1, respectively (Ghanem et al, 2007; Gonzalez et al, 1996; Ohtsu et al, 2002; 
Perez et al, 1995; Toyoda, et al, 1996; Zurcher et al, 1996; Poole et al, 1981). 
Thus, some structures and functions of PB1 have been clarified (He et al, 2008; 
Obayashi et al, 2008; Sugiyama et al, 2009).  However, the relationship between 
the structure and function are not clarified.  Therefore, to clarify this relationship, I 
started the functional analysis of PB1 subunit using ribavirin.  Ribavirin inhibits 
viral RNA synthesis as an analog of both adenine and guanine, and causes 
mutations in RNA dependent replication in RNA viruses as well as influenza 
viruses.  To isolate a ribavirin-resistant PB1 mutant(s), I screened this resistance 
from the PB1 mutant library by the mini-replicon assay using EGFP gene (Fig. 
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15A).  In addition, to know influenza virus RNA polymerase activity of D27N, 
luciferae assay was carried out in the presence of various concentrations of 
ribavirin (Fig. 16C).  It was shown that the luciferase activity of this mutant was 
higher than that of wild type.  In addition, the viral polymerase activity of D27N 
was also resistant to MTX treatment compared with wild type (Fig. 17).  It is 
possible that the nucleotide recognition activity of D27N is higher than that of 
wild-type.  
The Asp amino acid at position 27 of PB1 is conserved over 99.9% of 7,259 
sequences of PB1 deposited in the NCBI Influenza Sequence Database.  It has 
been reported that D27 is located at upstream of nucleotide binding site of PB1 
but not the catalytic active site.  Similarly, the ribavirin-resistant mutant of polio 
virus has a mutation in a domain not belonging to the catalytic domain of viral 
RNA polymerase (Pfeiffer et al, 2003).  D27N is also present within putative 
vRNA and cRNA promoter binding sites (Gonzalez et al, 1999a; Gonzalez et al, 
1999b) (Fig. 3A).  The cRNA and vRNA promoter structures are different 
substantially (Park et al, 2003; Tchatalbachev et al, 2001).  Biochemical studies 
have shown that conformational changes in PB1 of the influenza A virus RNA 
polymerase lead to the interaction with either vRNA or cRNA (Gonzalez et al, 
1999b).  Based on previous reports and our findings, the interaction between 
asparagine at position 27 in PB1 with RNA promoters may lead to the regulation 
of RNA polymerase activity and the nucleotide recognition of PB1 subunit.  This 
finding is extended for further study about mechanism of nucleotide recognition 
of influenza viral  RNA polymerase. 
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Chapter IV. Overview and Prospects 
 
The influenza virus genome forms viral ribonucleoprotein (vRNP) complexes 
with nucleoprotein and viral RNA polymerases, PB1, PB2, and PA subunits.  The 
vRNP complex catalyzes both replication and transcription reactions (Nagata et 
al, 2008).  PB1 contains the motifs highly conserved among RNA-dependent 
RNA polymerases (Biswas et al, 1994) and functions as a catalytic subunit of 
RNA chain elongation (Biswas et al, 1996; Gozalez et al, 1996; Ohtsu et al, 2002; 
Zurcher et al, 1996).  (Ghanem et al, 2007; Gonzalez et al, 1996; Ohtsu et al, 
2002; Perez et al, 1995; Toyoda, et al, 1996; Zurcher et al, 1996; Poole et al, 
1981).  Thus, some structures and functions of PB1 have been clarified (He et al, 
2008; Obayashi et al, 2008; Sugiyama et al, 2009).  However, the relationship 
between the structure and function are not clarified.  Therefore, to clarify this 
relationship, I started the functional analysis of PB1 subunit using mutant viruses 
by determining the catalytic active site of PB1 such as sites for polymerization, 
nucleotide recognition, and so on, with forward genetics and reverse genetics.  
For forward genetics, to elucidate the functional domain involved in the 
nucleotide recognition of PB1, I started to isolate ribavirin-resistant mutants.  
Ribavirin inhibits viral RNA synthesis and may cause mutations in the genome of 
influenza virus.  I isolated D27N and the viral polymerase activity of D27N was 
higher than that of wild type in the presence of ribavirin (Fig. 16C).  In addition, 
the viral polymerase activity of D27N was also resistant to MTX treatment 
compared with wild type (Fig. 17).  It is possible that the nucleotide recognition 
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activity of D27N is higher than that of wild-type.  
Alignment of amino acid sequences of PB1 subunit showed that this position is 
not conserved between influenza A and B viruses, this mutation also isolated 
from H4N8 strain- infected least sandpiper.  PB1 subunit of this strain contains 
asparagine at the position 27 (GenBank: ACI90144.1).  In addition, D27N mutant 
at this position also belongs to cRNA and vRNA promoter binding sites (Fig. 16D).  
I found that asparagine at position 27 in PB1 is responsible for ribavirin and MTX 
resistance (Fig. 16C and 17).  This finding is extended for further study about 
mechanism of nucleotide recognition of influenza viral RNA polymerase.  For 
reverse genetics, I analyzed function of PB1 subunit using mutant viruses.  The 
C-terminal region of PB1 between a.a. positions 494-757 contains a putative 
vRNA promoter binding site, while the N-terminal region of PB1 between a.a. 
positions 1-83 contains both putative vRNA and cRNA promoter binding sites and 
PA binding site (Gozalez et al, 1999a) (Fig. 3A).  However, except for the PA 
binding site, the crystal structure and the function of the N-terminal region of PB1 
are poorly understood.  Here, we have examined the functional structure of the 
N-terminal region of PB1.  The regions between a.a. positions 1-50 are highly 
conserved between influenza A and B viruses, but amino acids at positions 16, 
27, and 44 are different between two viruses (Fig. 3B).  To elucidate the 
functional importance of these amino acids in replication and transcription of the 
viral genome, I generated viruses containing mutations at these positions by 
reverse genetics and examined the replication and transcription activities of 
these mutants.  I found that a.a. positions 27 and 44 are responsible for the viral 
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replication activity but not transcription activity.  These positions may affect to the 
binding between PB1 subunit and cRNA promoter sites, resulting in its catalytic 
increase or decrease.  This findings may be based on for further study about the 
interaction between PB1 and promoter mutants.  
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Table 1.  Primers for preparation of PB1 mutants 
Position        Forward primer sequence (5’-3’)          Reverse primer sequence (5’-3’)  
N16A CACAAGCTGCTATAAGCACAACTTTC CTGGCACTTTTAAGAAAAGTAAAGTCG 
N16D  CACAAGATGCTATAAGCACAACTTTC CTGGCACTTTTAAGAAAAGTAAAGTCG 
N16Q   CACAACAAGCTATAAGCACAACTTTC CTGGCACTTTTAAGAAAAGTAAAGTCG 
D27N           CTTATACTGGAAACCCTCCTTAC GGAAAGTTGTGCTTATAGCATTTTGTGC 
D27E           CTTATACTGGAGAGCCTCCTTAC GGAAAGTTGTGCTTATAGCATTTTGTGC 
D27V           CTTATACTGGAGTCCCTCCTTAC GGAAAGTTGTGCTTATAGCATTTTGTGC 
N44I  ATCAGGACACATCAGTACTCAGAAAG GACAGTATCCATGGTGTATC 
N44D GACAGGACACATCAGTACTCAGAAAG GACAGTATCCATGGTGTATC 
N44Q  CAGAGGACACATCAGTACTCAGAAAG GACAGTATCCATGGTGTATC 
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A. Structure of influenza A virus    
 
 
 
 
B. Structure of viral genome 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1. (A) Structure of influenza A virus.  Influenza A virus contains eight 
segmented and single- and negative-stranded RNAs (vRNA) as its genome.  
Each segment is encapsidated by NP and associated with the RNA polymerase 
to form viral ribonucleoprotein (vRNP) complex.  The vRNP complex (PB1, PB2, 
PA, and NP) is a basic unit for both transcription and replication.  (B) Structure of 
viral genome. 
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Fig. 2. Transcription and replication of influenza virus.  The viral mRNA 
transcription is initiated using capped oligonucleotide as a primer derived from 
host cellular pre-mRNA. The elongation of mRNA chain proceeds until the viral 
polymerase reaches oligo U sequence, and then the polyA tail is added by viral 
RNA polymerase. In contrast, the viral genome is replicated in a primer-
independent manner to generate full-length cRNA from vRNA, and progeny 
vRNA is copied from the cRNA by the viral polymerase.  
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A. A schematic representation of PB1 
 
 
 
 
 
 
B. Alignment of amino acid sequences of putative vRNA and cRNA 
promoters  among influenza A and influenza B viruses 
 
 
 
 
 
 
 
 
 
16 27 44
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Fig. 3. Structure of PB1 subunit.  (A) A diagrammatic representation of PB1.  Red 
bar, cRNA promoter binding sites ; blue bar, vRNA promoter binding sites ; 
orange bar, nucleotide binding sites ; pink bar, PB2 binding site ; violet bar, PA 
binding site, and green bar, RNA dependent-RNA polymerase catalytic domains.  
(B) Alignment of amino acid sequences of putative RNA binding region common 
to vRNA and cRNA promoters (1-50 a.a.) among influenza A and influenza B 
viruses.  PB1 sequences of A/WSN/33, A/WSN/1933 (H1N1) ; A/England/67, 
A/England/10/67 (H2N2) ; A/Hong Kong/68, A/Hong Kong/1/1968 (H3N2) ; 
A/Narita/98, A/parakeet/Narita/92A/98 (H9N2).  These strains are picked up from 
different clades and periods of PB1 gene phylogenetic tree (33); B/Aichi/88, 
B/Aichi/5/88 ; B/Alaska/92, B/Alaska/03/1992 ; B/Argentina/01, 
B/Argentina/132/2001 ; and B/Hong Kong/93, B/Hong Kong/02/1993.  
Sequences were aligned with CLUSTAL W2.  Asterisk (*) indicates positions 
which have a single, fully conserved residue; colon (:) indicates conservation 
between groups of strongly similar properties-scoring > 0.5 in the Gonnet PAM 
250 matrix, and dot (.) indicates conservation between groups of weakly similar 
properties-scoring =< 0.5 in the Gonnet PAM 250 matrix.  
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Fig. 4. Comparison of RNA synthesis of mutant influenza A viruses containing 
amino acids specific for influenza B viruses.  The amino acids, N, D, and N at the 
positions 16, 27, and 44 were mutated to A, V, and I, respectively.  MDCK cells 
were infected with mutant viruses at MOI of 2.5 and incubated at 37oC with 5% 
CO2.  At 3 and 6 hpi, the accumulation levels of viral mRNA (A), cRNA (B), and 
vRNA (C) were measured by qPCR, and the amounts of these RNAs were 
normalized by that of cellular actin mRNA.  These results are averages from 
three independent experiments with standard deviations, and the level of 
significance was determined by Student’s t  test (*, P < 0.05; **, P < 0.01). 
* 
** ** 
** 
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Fig. 5. Comparison of RNA synthesis of mutant influenza A viruses containing 
amino acids specific for influenza B viruses.  The amino acids, N, D, and N at the 
positions 16, 27, and 44 were mutated to A, V, and I, respectively.  MDCK cells 
were infected with mutant viruses at MOI of 2.5 and incubated at 37oC with 5% 
CO2.  At 9 hpi, the accumulation levels of viral mRNA (A), cRNA (B), and vRNA 
(C) were measured by qPCR, and the amounts of these RNAs were normalized 
by that of cellular actin mRNA.  These results are averages from three 
independent experiments with standard deviations, and the level of significance 
was determined by Student’s t  test (*, P < 0.05; **, P < 0.01). 
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Fig. 6. Primary transcription activity of mutant influenza A viruses containing 
amino acids specific to influenza B viruses (A), amino acid position 16 (B), amino 
acid position 27 (C), and amino acid position 44 (D).  MDCK cells were infected 
with mutant viruses at MOI of 2.5 and incubated at 37oC with 5% CO2 in the 
presence of 100 μg/ml of cycloheximide.  At 9 hpi, the accumulation levels of viral 
mRNA and vRNA were measured by qPCR, and the amounts of these RNAs 
were normalized by that of cellular actin mRNA.  The transcription activity is 
represented as a ratio of the amount of viral mRNA to that of vRNA.  These 
results are averages from three independent experiments with standard 
deviations, and the level of significance was determined by Student’s t  test.  
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Fig. 7. RNA synthesis of viruses containing mutations at the amino acid position 
16.  Wild-type virus and mutant viruses containing amino acids N and D, Q, and 
A, respectively, at the a.a. position 16 were infected into MDCK cells at MOI and 
incubated at 37oC with 5% CO2.  At 3 and 6 hpi, the accumulation levels of viral 
mRNA (A), cRNA (B), and vRNA (C) were measured by qPCR, and the amounts 
of these RNAs were normalized by that of cellular actin mRNA.  These results 
are averages from three independent experiments with standard deviations, and 
the level of significance was determined by Student’s t  test (*, P < 0.05; **, P < 
0.01). 
* 
** 
** ** 
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Fig. 8. RNA synthesis of viruses containing mutations at the amino acid position 
16.  Wild-type virus and mutant viruses containing amino acids N and D, Q, and 
A, respectively, at the a.a. position 16 were infected into MDCK cells at MOI and 
incubated at 37oC with 5% CO2.  At 9 hpi, the accumulation levels of viral mRNA 
(A), cRNA (B), and vRNA (C) were measured by qPCR, and the amounts of 
these RNAs were normalized by that of cellular actin mRNA.  These results are 
averages from three independent experiments with standard deviations, and the 
level of significance was determined by Student’s t  test (*, P < 0.05; **, P < 0.01). 
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Fig. 9. RNA synthesis of viruses containing mutations at the amino acid position 
27.  Wild-type virus and mutant viruses containing amino acids D and E, N, and V, 
respectively, at the a.a. position 27 were infected into MDCK cells at MOI and 
incubated at 37oC with 5% CO2.  At 3 and 6 hpi, the accumulation levels of viral 
mRNA (A), cRNA (B), and vRNA (C) were measured by qPCR, and the amounts 
of these RNAs were normalized by that of cellular actin mRNA. These results are 
averages from three independent experiments with standard deviations, and the 
level of significance was determined by Student’s t  test (*, P < 0.05; **, P < 0.01). 
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Fig. 10. RNA synthesis of viruses containing mutations at the amino acid position 
27.  Wild-type virus and mutant viruses containing amino acids D and E, N, and V, 
respectively, at the a.a. position 27 were infected into MDCK cells at MOI and 
incubated at 37oC with 5% CO2.  At 9 hpi, the accumulation levels of viral mRNA 
(A), cRNA (B), and vRNA (C) were measured by qPCR, and the amounts of 
these RNAs were normalized by that of cellular actin mRNA.  These results are 
averages from three independent experiments with standard deviations, and the 
level of significance was determined by Student’s t  test (*, P < 0.05; **, P < 0.01). 
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Fig. 11. RNA synthesis of viruses containing mutations at the amino acid position 
44.  Wild-type virus and mutant viruses containing amino acids N and I, D, and Q, 
respectively, at the a.a. position 44 were infected into MDCK cells at MOI and 
incubated at 37oC with 5% CO2.  At 3 and 6 hpi, the accumulation levels of viral 
mRNA (A), cRNA (B), and vRNA (C) were measured by qPCR, and the amounts 
of these RNAs were normalized by that of cellular actin mRNA.  These results 
are averages from three independent experiments with standard deviations, and 
the level of significance was determined by Student’s t  test (*, P < 0.05; **, P < 
0.01). 
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Fig. 12. RNA synthesis of viruses containing mutations at the amino acid position 
44.  Wild-type virus and mutant viruses containing amino acids N and I, D, and Q, 
respectively, at the a.a. position 44 were infected into MDCK cells at MOI and 
incubated at 37oC with 5% CO2.  At 9 hpi, the accumulation levels of viral mRNA 
(A), cRNA (B), and vRNA (C) were measured by qPCR, and the amounts of 
these RNAs were normalized by that of cellular actin mRNA.  These results are 
averages from three independent experiments with standard deviations, and the 
level of significance was determined by Student’s t  test (*, P < 0.05; **, P < 0.01). 
 
 
R
el
at
iv
e 
am
ou
nt
 o
f v
R
N
A 3
0
0.5
1
1.5
2
2.5
mock wt N44I N44D N44Q
C.   vRNA 
R
el
at
iv
e 
am
ou
nt
 o
f  
m
R
N
A
0
0.5
1
1.5
2
2.5
3
mock wt N44I N44D N44Q
A.   mRNA
R
el
at
iv
e 
am
ou
nt
 o
f c
R
N
A
0
0.5
1
1.5
2
2.5
3
mock wt N44I N44D N44Q
B.   cRNA 
R
el
at
iv
e 
am
ou
nt
 o
f v
R
N
A
R
el
at
iv
e 
am
ou
nt
 o
f v
R
N
A
R
el
at
iv
e 
am
ou
nt
 o
f v
R
N
A
R
el
at
iv
e 
am
ou
nt
 o
f  
m
R
N
A
R
el
at
iv
e 
am
ou
nt
 o
f c
R
N
A
R
el
at
iv
e 
am
ou
nt
 o
f  
m
R
N
A
R
el
at
iv
e 
am
ou
nt
 o
f  
m
R
N
A
R
el
at
iv
e 
am
ou
nt
 o
f  
m
R
N
A
R
el
at
iv
e 
am
ou
nt
 o
f c
R
N
A
R
el
at
iv
e 
am
ou
nt
 o
f c
R
N
A
R
el
at
iv
e 
am
ou
nt
 o
f c
R
N
A
** 
** ** 
** 
 50 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 13. RNA synthesis of D27V virus at various moi.  Wild-type virus and mutant 
virus containing V at the a.a. position 27 were infected into MDCK cells at various 
MOI (0.5, 2.5, 10, and 25) and incubated at 37oC with 5% CO2.  At 9 hpi, the 
accumulation levels of viral mRNA (A), cRNA (B), and vRNA (C) were measured 
by qPCR, and the amounts of these RNAs were normalized by that of cellular 
actin mRNA. These results are averages from three independent experiments 
with standard deviations, and the level of significance was determined by 
Student’s t  test (*, P < 0.05; **, P < 0.01). 
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Fig. 14. Effect of mutations on assembly of viral RNA polymerase complexes.  
MDCK cells were infected with wild type or mutant viruses at MOI of 1 PFU.  At 7 
hpi, cells were lysed by sonication.  RNA polymerase complexes in the 
supernatant fraction were subjected to immunoprecipitation with rabbit anti-PB2 
antibody.  Immunoprecipitated proteins were subjected to western blotting 
analysis.  (A) Expression levels of PB2 in infected cells.  The amount of PB2 and 
β-tubulin were determined by western blotting.  (B) The interactions of PB2 and 
PA with PB1 in infected cells.  Immunoprecipitation was carried out with (lanes 1 
and 3-12) or without (lane 2) anti-PB2.  PB1, PB2, and PA in the 
immunoprecipitated complex were detected by western blotting.  The ratio of the 
amount of PB1 to that of PA is shown under each lane. 
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Fig. 15. Screening of ribavirin-resistant PB1 mutant.  (A) Assay system for 
screening by mini-replicon assay.  293T cells  were transfected with plasmids for 
the expression of viral proteins, PB1 (wt or mutated-type of each group), PB2, PA, 
and NP, and a plasmid for the expression of artificial influenza virus genome 
containing EGFP gene of negative polarity.  (B) EGFP fluorescence in the first 
screening.  After 3 hours of transfection, ribavirin was added (0 or 75 µM) and the 
fluorescence of EGFP was observed at 15 hpt.  G1-G10 indicate each groups 
divided mutated PB1 library. 
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Fig. 16. Ribavirin-resistance of D27N mutant by mini-replicon assay system.  (A) 
Sequencing of  ribavirin-resistant PB1 mutant.  (B) Mini-replicon assay using 
EGFP gene as a reporter gene.  After 3 hours of transfection, ribavirin was added 
(0 or 75 µM) and the fluorescence of EGFP was observed at 15 hpt.  The ratio of 
the ribavirin presence and absence in the medium was shown in right side.  (C) 
Mini-replicon assay using luciferase gene as a reporter gene was carried out.  
After 3h of transfection, ribavirin different concentrations 0, 12.5, 25, and 50 were 
added, and luciferase activity was measured at 15 hpt.  % control indicates that 
the percentage of ribavirin-treated and-untreated cells per ribavirin-untreated 
cells (D) Effect of D27N mutation on assembly of PB1 subunit.  Mini-replicon 
assay using luciferase gene as a reporter gene was carried out.  After 3 hours of 
transfection, ribavirin was added (0 or 50 µM).  At 15 hpt, cells were lysed and 
this lysates were subjected to western blot analysis using anti-PB1 antibody and 
antibody against β-tubulin.  
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Fig. 17. Methotrexate-resistance of D27N mutant by mini-replicon assay system.  
Mini-replicon assay using luciferase gene as a reporter gene was carried out.  At 
12 hpt, different concentrations (0, 0.3, 1, 3, 10, and 30 µM) of methotrexate 
were added, and luciferase activity was measured at 22 hpt.  % of control 
indicates that the percentage of the luciferase activity from methotrexate -treated 
and -untreated cells per methotrexate -untreated cells. 
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